Thalidomide-PEG5-NH2

filler

Catalog No. Size 价格库存数量
S1316-2 Contact sales@xcessbio.com for quotation ¥100
售罄
不可用
S1316-10 Contact sales@xcessbio.com for quotation ¥100
售罄
不可用

详情描述

Thalidomide-PEG5-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

Product information

CAS Number: 2460263-40-3

Molecular Weight: 493.51

Formula: C23H31N3O9

Chemical Name: 5-[(14-amino-3, 6, 9, 12-tetraoxatetradecan-1-yl)oxy]-2-(2, 6-dioxopiperidin-3-yl)-2, 3-dihydro-1H-isoindole-1, 3-dione

Smiles: NCCOCCOCCOCCOCCOC1=CC2=C(C=C1)C(=O)N(C1CCC(=O)NC1=O)C2=O

InChiKey: DPRIQEUNSVIIDM-UHFFFAOYSA-N

InChi: InChI=1S/C23H31N3O9/c24-5-6-31-7-8-32-9-10-33-11-12-34-13-14-35-16-1-2-17-18(15-16)23(30)26(22(17)29)19-3-4-20(27)25-21(19)28/h1-2,15,19H,3-14,24H2,(H,25,27,28)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

References:

  1. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-1005.
  2. Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine. Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11.

Products are for research use only. Not for human use.

相似产品

Recently viewed